名稱 | CSF1R/HEK293 |
型號 | CBP74048 |
報價 | |
特點 | CSF1R/HEK293,凍存條件:90% FBS+10% DMSO |
產(chǎn)品搜索
相關文章
聯(lián)系我們
聯(lián)系人:蔣經(jīng)理
電話:4008750250
號碼:
手機:18066071954
地址:南京市棲霞區(qū)緯地路9號
Email: zhangxiangwen@cobioer.com
電話:4008750250
號碼:
手機:18066071954
地址:南京市棲霞區(qū)緯地路9號
Email: zhangxiangwen@cobioer.com
產(chǎn)品展示 / PRODUCTS
- 詳細內(nèi)容
CBP74048 | |
I. Background | |
Colony Stimulating Factor 1 Receptor (CSF1R, CSFR, CD115, M-CSF-R) is a single-pass tyrosine kinase transmembrane receptor which is part of the type III protein tyrosine kinase receptor family. CSF1R is activated by either of two cytokines, CSF1 (MCSF; CSF-1) and IL-34 (IL34), causing homodimerization and activation of downstream kinase activity. CSF1R is expressed on the surface of monocytes and macrophages, and its activation controls the growth, function, and differentiation of macrophages. This interaction is used by numerous cancer types, such as diffuse-type tenosynovial giant cell tumors (dt-GCT), to evade the immune system. By overexpressing the cytokine CSF1, these cells drive the development and survival of Tumor-Associated Macrophages (TAMs), which in turn suppress the local immune response to the cancer. | |
II. Description | |
Recombinant HEK293 stably expressing human CSF1R (full-length human CSF1R cDNA (NP_005202) ). | |
III. Introduction | |
Host Cell: | HEK293 |
Expressed gene: | CSF1R |
Stability: | 32 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
Synonym(s): | CSF1R, CSFR, CD115, M-CSF-R |
Freeze Medium: | 90% FBS+10% DMSO |
Culture Medium: | DMEM+10%FBS+1ug/ml puromycin |
Mycoplasma Testing: | Negative |
Storage: | Liquid nitrogen. |
Application(s): | Binding Assay,FACS |
IV. Description of Host Cell Line | |
Organism: | Homo sapiens,human |
Tissue: | Embryonic kidney |
Disease: | Normal |
Morphology: | Epitheloid cell |
Growth Properties: | Adherent |
Ⅴ. Representative Data | |
Figure 1. Recombinant HEK293 stably expressing human CSF1R (full-length human CSF1R cDNA (NP_005202) ). |